Thrombotic recurrences and bleeding events in APS vascular patients: A review from the literature and a comparison with the APS Piedmont Cohort

被引：22

作者：

Bazzan, M. ^{[1
]}

Vaccarino, A. ^{[1
]}

Stella, S. ^{[1
]}

Bertero, M. T. ^{[2
]}

Carignola, R. ^{[3
]}

Montaruli, B. ^{[4
]}

Roccatello, D. ^{[5
,6
]}

Shoenfeld, Y. ^{[7
]}

Giachino, Osvaldo

Fabio, Marletto

Baldovino, Simone

Sosso, Luisa

Marozio, Luca

Data, Valeria

Guida, Giuseppe

Bigo, Patrizia

Rollino, Cristiana

Ferro, Michela

Loredana, Colla

Karvela, Eirini

Pellerito, Raffaele

Emanuela, Bellis

Maina, Aldo

Donvito, Valentina

Nicolino, Barbara

Schinco, Piercarla

Sivera, Piera

Kuzenko, Anna

Napolitano, Emanuela

Cosseddu, Domenico

Marchese, Cristiana

Romeo, Nicoletta

Seminara, Giulia

Erato, Maria Stefanidou

Molinari, Filippo

Contino, Laura

Santi, Roberto

Nallino, Gabriella Maria

Calvi, Roberta

Stratta, Piero

Bizzocchi, Agata

Flavio, Bobbio

Sainaghi, Paolo Pier

Sola, Daniele

机构：

[1] Giovanni Bosco Hosp, Haematol & Thrombosis Unit, Dept Rare Immunol Hematol Dis & Transfus Med, Turin, Italy

[2] Umberto I Hosp, Turin, Italy

[3] San Luigi Gonzaga Hosp, Turin, Italy

[4] Umberto I Hosp, Haemostasis Lab, Turin, Italy

[5] Giovanni Bosco Hosp, Dept Rare Immunol Hematol Dis & Transfus Med, Res Ctr Immunopathol & Rare Dis CMID, Turin, Italy

[6] Univ Turin, I-10124 Turin, Italy

[7] Chaim Sheba Med Ctr, Res Ctr Autoimmune Dis, Tel Hashomer, Israel

来源：

AUTOIMMUNITY REVIEWS | 2013年 / 12卷 / 08期

关键词：

Antiphospholipid syndrome; Thrombosis; Thrombotic recurrences; DEFINITE ANTIPHOSPHOLIPID SYNDROME; INTERNATIONAL CONSENSUS STATEMENT; DEEP VENOUS THROMBOSIS; RISK-FACTORS; ANTIBODY-SYNDROME; CLASSIFICATION CRITERIA; ASYMPTOMATIC CARRIERS; ANTICOAGULANT-THERAPY; ORAL ANTICOAGULATION; ISCHEMIC-STROKE;

D O I：

10.1016/j.autrev.2012.11.007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

071005 [微生物学]; 100108 [医学免疫学];

摘要：

In APS vascular patients, thrombotic recurrences are more frequent than in non-APS thrombotic patients. To better define this clinical setting, a systematic review of the literature after 1999 was performed: 8 cohort studies (including the recent APS Piedmont Cohort) and 6 intervention studies were selected and evaluated. Thrombotic recurrences, bleeding events, therapeutic strategies, antiphospholipid (aPL) profile, inherited and acquired risk factors (when present) were calculated and compared. Emerging risk factors for thrombotic recurrences include withdrawal of oral anticoagulant therapy (OAT), high intensity OAT (INR range 3-4), aPL profile (triple positivity, Miyakis types 1 and 2a profiles) and association with inherited or acquired pro-thrombotic risk factors. Moreover, there are evidences that high risk (mainly for aPL profile) APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this clinical setting are needed. (C) 2012 Elsevier B.V. All rights reserved.

引用

页码：826 / 831

页数：6

共 43 条

[1]

Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. [J].

Agnelli, G ;

Prandoni, P ;

Santamaria, MG ;

Bagatella, P ;

Iorio, A ;

Bazzan, M ;

Moia, M ;

Guazzaloca, G ;

Bertoldi, A ;

Tomasi, C ;

Scannapieco, G ;

Ageno, W ;

Ascani, A ;

Villalta, S ;

Frulla, M ;

Mosena, L ;

Girolami, A ;

Vaccarino, A ;

Alatri, A ;

Palareti, G ;

Marchesi, M ;

Ambrosio, GB ;

Parisi, R ;

Doria, S ;

Steidl, L ;

Ambrosini, F ;

Silingardi, M ;

Ghirarduzzi, A ;

Iori, I .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :165-169

[2]

Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation - An 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia [J].

Ames, PRJ ;

Ciampa, A ;

Margaglione, M ;

Scenna, G ;

Iannaccone, L ;

Brancaccio, V .

THROMBOSIS AND HAEMOSTASIS, 2005, 93 (04) :694-699

[3]

Antiphospholipid syndrome in northwest Italy (APS Piedmont Cohort): demographic features, risk factors, clinical and laboratory profile [J].

Bertero, M. T. ;

Bazzan, M. ;

Carignola, R. ;

Montaruli, B. ;

Silvestro, E. ;

Sciascia, S. ;

Vaccarino, A. ;

Baldovino, S. ;

Roccatello, D. ;

Osvaldo, Giachino ;

Fabio, Marletto ;

Luisa, Sosso ;

Luca, Marozio ;

Valeria, Data ;

Giuseppe, Guida ;

Patrizia, Bigo ;

Stefania, Stella ;

Cristiana, Rollino ;

Michela, Ferro ;

Loredana, Colla ;

Eirini, Karvela ;

Raffaele, Pellerito ;

Emanuela, Bellis ;

Aldo, Maina ;

Valentina, Donvito ;

Barbara, Nicolino ;

Piercarla, Schinco ;

Piera, Sivera ;

Anna, Kuzenko ;

Emanuela, Napolitano ;

Domenico, Cosseddu ;

Cristiana, Marchese ;

Nicoletta, Romeo ;

Giulia, Seminara ;

Maria, Stefanidou Erato ;

Filippo, Molinari ;

Laura, Contino ;

Roberto, Santi ;

Maria, Nallino ;

Roberta, Calvi ;

Piero, Stratta ;

Agata, Bizzocchi ;

Flavio, Bobbio ;

Sainaghi, Pier Paolo ;

Daniele, Sola .

LUPUS, 2012, 21 (07) :806-809

[4]

Cabral AR, 2004, JAMA-J AM MED ASSOC, V291, P2701, DOI 10.1001/jama.291.22.2701-a

[5]

Migraineurs show a high prevalence of antiphospholipid antibodies [J].

Cavestro, C. ;

Micca, G. ;

Molinari, F. ;

Bazzan, M. ;

Di Pietrantonj, C. ;

Aloi, R. ;

Pedemonte, E. ;

Iannini, R. ;

Frigeri, M. C. ;

Roccatello, D. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (07) :1350-1354

[6]

Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients [J].

Cervera, R ;

Piette, JC ;

Font, J ;

Khamashta, MA ;

Cervera, R ;

Piette, JC ;

Font, J ;

Khamashta, MA ;

Shoenfeld, Y ;

Camps, MT ;

Jacobsen, S ;

Lakos, G ;

Tincani, A ;

Kontopoulou-Griva, I ;

Galeazzi, M ;

Meroni, PL ;

Derksen, RHWM ;

de Groot, PG ;

Gromnica-Ihle, E ;

Baleva, M ;

Mosca, M ;

Bombardieri, S ;

Houssiau, F ;

Gris, JC ;

Quéré, I ;

Hachulla, E ;

Vasconcelos, C ;

Roch, B ;

Fernández-Nebro, A ;

Boffa, MC ;

Hughes, GRV ;

Ingelmo, M .

ARTHRITIS AND RHEUMATISM, 2002, 46 (04) :1019-1027

[7]

Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients [J].

Cervera, R. ;

Khamashta, M. A. ;

Shoenfeld, Y. ;

Camps, M. T. ;

Jacobsen, S. ;

Kiss, E. ;

Zeher, M. M. ;

Tincani, A. ;

Kontopoulou-Griva, I. ;

Galeazzi, M. ;

Bellisai, F. ;

Meroni, P. L. ;

Derksen, R. H. W. M. ;

de Groot, P. G. ;

Gromnica-Ihle, E. ;

Baleva, M. ;

Mosca, M. ;

Bombardieri, S. ;

Houssiau, F. ;

Gris, J-C ;

Quere, I. ;

Hachulla, E. ;

Vasconcelos, C. ;

Roch, B. ;

Fernandez-Nebro, A. ;

Piette, J-C ;

Espinosa, G. ;

Bucciarelli, S. ;

Pisoni, C. N. ;

Bertolaccini, M. L. ;

Boffa, M-C ;

Hughes, G. R. V. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (09) :1428-1432

[8]

Does seronegative antiphospholipid syndrome really exist? [J].

Cervera, Ricard ;

Conti, Fabrizio ;

Doria, Andrea ;

Iaccarino, Luca ;

Valesini, Guido .

AUTOIMMUNITY REVIEWS, 2012, 11 (08) :581-584

[9]

A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome [J].

Crowther, MA ;

Ginsberg, JS ;

Julian, J ;

Denburg, J ;

Hirsh, J ;

Douketis, J ;

Laskin, C ;

Fortin, P ;

Anderson, D ;

Kearon, C ;

Clarke, A ;

Geerts, W ;

Forgie, M ;

Green, D ;

Costantini, L ;

Yacura, W ;

Wilson, S ;

Gent, M ;

Kovacs, MJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (12) :1133-1138

[10]

Evidence based treatment of the anti phospholipid syndrome II. Optimal anticoagulant therapy for thrombosis [J].

Crowther, MA ;

Wisloff, F .

THROMBOSIS RESEARCH, 2005, 115 (1-2) :3-8

← 1 2 3 4 5 →